Abstract
Ulcerative colitis (UC) and Crohn’s disease (CD) constitute the two major groups of idiopathic disorders in inflammatory bowel disease (IBD). Environmental factors, genetic factors and immune responses have been considered as the major etiology of IBD. Despite the diversified pathogenesis of the disease, no guaranteed curative therapeutic regimen has been developed so far. This review summarizes the knowledge on the pathophysiology and current treatment approaches of IBD. Since IBD is caused by excessive and tissue- disruptive inflammatory reactions of the gut wall, down-regulation of the immune responses may allow the damaged mucosa to heal and reset the physiological functions of the gut back to normal. Current pharmacotherapy through modulation of neutrophil-derived factors, cytokines, adhesion molecules and reactive oxygen/nitrogen metabolites has been utterly described. Categories of treatment modalities include corticosteroids, aminosalicylates, immunomodulators, antibiotics, probiotics, and a series of unique novel agents. The use of anti-tumor necrosis factor monoclonal antibody (Infliximab), recombinant anti-inflammatory cytokines and related gene therapy has been covered. In addition, discussions on dietary supplementation and heparin treatment are also included. The anti-inflammatory and immunoregulatory potential of investigational agents such as nicotine and the filtered protective compounds from tobacco smoke, as well as active herbal medicinal compounds were tested in our previous experimental works, whereas promising findings have been presented here. With the discovery of novel target-oriented agents, more effective and relatively harmless approaches of IBD therapy could be established to achieve a curative outcome. Indeed, more experimental and clinical studies are needed to confirm the relevance of these therapies.
Keywords: Inflammatory bowel disease, neutrophils, cytokines, adhesion molecules, immunomodulation, reactive oxygen/nitrogen metabolites, pharmacotherapy.
Current Pharmaceutical Design
Title:Inflammatory Bowel Disease: Etiology, Pathogenesis and Current Therapy
Volume: 20 Issue: 7
Author(s): Joshua K. Ko and Kathy K. Auyeung
Affiliation:
Keywords: Inflammatory bowel disease, neutrophils, cytokines, adhesion molecules, immunomodulation, reactive oxygen/nitrogen metabolites, pharmacotherapy.
Abstract: Ulcerative colitis (UC) and Crohn’s disease (CD) constitute the two major groups of idiopathic disorders in inflammatory bowel disease (IBD). Environmental factors, genetic factors and immune responses have been considered as the major etiology of IBD. Despite the diversified pathogenesis of the disease, no guaranteed curative therapeutic regimen has been developed so far. This review summarizes the knowledge on the pathophysiology and current treatment approaches of IBD. Since IBD is caused by excessive and tissue- disruptive inflammatory reactions of the gut wall, down-regulation of the immune responses may allow the damaged mucosa to heal and reset the physiological functions of the gut back to normal. Current pharmacotherapy through modulation of neutrophil-derived factors, cytokines, adhesion molecules and reactive oxygen/nitrogen metabolites has been utterly described. Categories of treatment modalities include corticosteroids, aminosalicylates, immunomodulators, antibiotics, probiotics, and a series of unique novel agents. The use of anti-tumor necrosis factor monoclonal antibody (Infliximab), recombinant anti-inflammatory cytokines and related gene therapy has been covered. In addition, discussions on dietary supplementation and heparin treatment are also included. The anti-inflammatory and immunoregulatory potential of investigational agents such as nicotine and the filtered protective compounds from tobacco smoke, as well as active herbal medicinal compounds were tested in our previous experimental works, whereas promising findings have been presented here. With the discovery of novel target-oriented agents, more effective and relatively harmless approaches of IBD therapy could be established to achieve a curative outcome. Indeed, more experimental and clinical studies are needed to confirm the relevance of these therapies.
Export Options
About this article
Cite this article as:
Ko K. Joshua and Auyeung K. Kathy, Inflammatory Bowel Disease: Etiology, Pathogenesis and Current Therapy, Current Pharmaceutical Design 2014; 20 (7) . https://dx.doi.org/10.2174/13816128113199990416
DOI https://dx.doi.org/10.2174/13816128113199990416 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immunogenicity and Tumorigenicity of Pluripotent Stem Cells and their Derivatives: Genetic and Epigenetic Perspectives
Current Stem Cell Research & Therapy Discovery and Development of Natural Products and their Derivatives as Photosensitizers for Photodynamic Therapy
Current Medicinal Chemistry Innate T-Cell Immunity in HIV Infections: The Role of Vg9Vd2 T Lymphocytes
Current Molecular Medicine Diketoacid Inhibitors of HIV-1 Integrase: From L-708,906 to Raltegravir and Beyond
Current Medicinal Chemistry In Situ Modulation of Oxidative Stress: A Novel and Efficient Strategy to Kill Cancer Cells
Current Medicinal Chemistry EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance
Current Molecular Pharmacology Green Tea Catechins as Novel Antitumor and Antiangiogenic Compounds
Current Medicinal Chemistry - Anti-Cancer Agents NF-κB Inhibitors in Head and Neck Cancer
Letters in Drug Design & Discovery Dicoumarol: A Drug which Hits at Least Two Very Different Targets in Vitamin K Metabolism
Current Drug Targets Preclinical Evaluation of New Anthracyclines
Current Medicinal Chemistry Understanding Effects of Psychological Stress on Physiology and Disease Through Human Stressome - An Integral Algorithm
Current Bioinformatics Overview of Hyperuricaemia and Gout
Current Pharmaceutical Design ANN-QSAR Model for Virtual Screening of Androstenedione C-Skeleton Containing Phytomolecules and Analogues for Cytotoxic Activity Against Human Breast Cancer Cell Line MCF-7
Combinatorial Chemistry & High Throughput Screening Treatment of Acute Leukaemias with Monoclonal Antibodies: Current Status and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Short- and Long-Term Survival of Nonsurgical Intensive Care Patients and its Relation to Diagnosis, Severity of Disease, Age and Comorbidities
Current Aging Science Pathophysiology of Preeclampsia and Possible Role of Zinc in its Genesis
Current Women`s Health Reviews Barminomycin, a Model for the Development of New Anthracyclines
Anti-Cancer Agents in Medicinal Chemistry The Significance of Transferrin Receptors in Oncology: the Development of Functional Nano-based Drug Delivery Systems
Current Drug Delivery Protein Tyrosine Phosphatases: Strategies for Distinguishing Proteins in a Family Containing Multiple Drug Targets and Anti-Targets
Current Pharmaceutical Design MicroRNAs in Colorectal Neoplasia: From Pathobiology to Clinical Applications
Current Pharmaceutical Biotechnology